Takeaways: Leqembi’s positive reimbursement step in Canada is a meaningful commercial win because it could unlock public coverage for the first disease-modifying Alzheimer’s therapy in the count...
Takeaways Skyhawk’s global Phase 2/3 FALCON-HD program for SKY-0515 positions the company as a front-runner in disease‑modifying treatment for Huntington’s disease, and if successful, a once‑dai...
Takeaways: Kisunla adds a new money‑maker for Lilly in Canada, but real sales will depend on how fast the system can diagnose patients early and pay for the drug. Because testing and speci...
